Dobi Medical completes private placement

Article

Financial coffers at Dobi Medical have swelled following the private placement of $5.16 million in shares of its Series A Preferred stock and warrants. The shares carry a dividend of 8% per year and are convertible into 2,580,667 shares of common stock.

Financial coffers at Dobi Medical have swelled following the private placement of $5.16 million in shares of its Series A Preferred stock and warrants. The shares carry a dividend of 8% per year and are convertible into 2,580,667 shares of common stock. Proceeds from the transaction will be used to build and begin internationally marketing the company's ComfortScan system, a noninvasive optical imaging system designed for use in the detection and management of breast cancer.

Financial results for the company in the second fiscal quarter of 2004, ended June 30, show a net loss of $1.6 million, or 4¢ per share, compared with a net loss of $1.1 million, or 6¢ per share in the same quarter last year. For the first six months of fiscal 2004, net loss was $3.0 million, or 8¢ per share, compared with a net loss of $2.3 million, or 12¢ per share in the previous year's period.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.